some hope?(Source: Susan Kelly, editing by Dave Zimmerman. Reuters. May 19, 2008)
Intermune were granted fast-track designation by the regulators for the development of pirfenidone to treat idiopathic pulmonary fibrosis (IPF), a deadly lung disease. This is a drug that supposedly has the potential to address something that has never been accomplished. "InterMune said there are no approved medicines to treat patients with IPF, an often fatal disease characterized by scarring and inflammation of the lungs."
Phase three results will be made available in January 2009.